HBM BIOVENTURES CAYMAN LTD 13D and 13G filings for Y-mAbs Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 4:08 pm Sale |
2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,297,800 7.600% |
-516,053 (-13.53%) |
Filing |
| 2023-02-14 4:03 pm Purchase |
2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,813,853 8.700% |
722,899 (+23.39%) |
Filing |
| 2022-02-07 5:13 pm Purchase |
2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 3,090,954 7.100% |
960,581 (+45.09%) |
Filing |
| 2021-02-12 4:00 pm Sale |
2020-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB |
HBM BIOVENTURES CAYMAN LTD | 2,130,373 5.300% |
-657,452 (-23.58%) |
Filing |